immuno oncology part of the broader field of cancer immunotherapy involves agents which harness the body s own immune system to fight cancer traditionally patient responses to new cancer treatments have been evaluated using two sets of criteria the who criteria and the response evaluation criteria in solid tumors recist the immune related response criteria first published in 2009 arose out of observations that immuno oncology drugs would fail in clinical trials that measured responses using the who or recist criteria because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune system to reduce the tumor burden part of the process of determining the effectiveness of anti cancer agents in clinical trials involves measuring the amount of tumor shrinkage such agents can generate the who criteria developed in the 1970s by the international union against cancer and the world health organization represented the first generally agreed specific criteria for the codification of tumor response evaluation these criteria were first published in 1981 the recist criteria first published in 2000 revised the who criteria primarily to clarify differences that remained between research groups under recist tumour size was